(2,6-dibromo-3-nitropyridin-4-yl)carbamic acid ethyl ester | 947145-05-3

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: (2,6-dibromo-3-nitropyridin-4-yl)carbamic acid ethyl ester
• 英文别名: ethyl (2,6-dibromo-3-nitropyridin-4-yl)carbamate；(2,6-dibromo-3-nitro-pyridin-4-yl)-carbamic acid ethyl ester；Ethyl (2,6-dibromo-3-nitropyridin-4-yl)carbamate；ethyl N-(2,6-dibromo-3-nitropyridin-4-yl)carbamate
• CAS: 947145-05-3
• 化学式: C₈H₇Br₂N₃O₄
• 分子量: 368.969
• InChiKey: MGRZHIOWGWOETP-UHFFFAOYSA-N

物化性质

• 沸点：
  348.6±42.0 °C(Predicted)
• 密度：
  2.018±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2,6-dibromo-3-nitropyridin-4-yl)carbamic acid ethyl ester 在 bis-triphenylphosphine-palladium(II) chloride 、 氨 、 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection

  摘要：

  The synthesis and structure-activity relationships of a series of novel interferon inducers are described. Pharmacokinetic studies and efficacy assessment of a series of 8-oxo-3-deazapurine analogues led to the identification of compound 33, a potent and selective agonist of the TLR7 receptor with an excellent in vivo efficacy profile in a mouse model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.092
• 作为产物：
  描述：

  2,6-dibromopyridin-4-yl-N-nitroamine 在 硫酸 、 三乙胺 作用下， 以 2-甲基四氢呋喃 为溶剂， 反应 3.58h， 生成 (2,6-dibromo-3-nitropyridin-4-yl)carbamic acid ethyl ester
  参考文献：
  名称：

  灵活合成4-氨基-1,3-二氢咪唑并[4,5 - c ]吡啶-2-酮核的C-6和N-1类似物

  摘要：

  描述了一种灵活的途径，该途径使得能够获得4-氨基-1,3-二氢咪唑并[4,5 - c ]吡啶-2-酮的衍生物。原始路线的选择性，反应安全性和低收率问题可以通过对该路线的关键改进加以解决，包括Negishi交叉偶联以及使用氨基甲酸酯作为保护基团和固有的羰基来源。新的途径可以改变C-6和N-1取代基。

  DOI：

  10.1016/j.tetlet.2011.08.119

文献信息

• NOVEL PHARMACEUTICALS
  申请人：Jones Peter

  公开号：US20070197478A1

  公开（公告）日：2007-08-23

  The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.

  本发明涉及公式（I）的免疫应答调节剂，通过对Toll样受体（TLRs）的激动作用具有选择性，其用途，其制备方法，用于其制备的中间体以及含有所述抑制剂的组合物。这些抑制剂在包括治疗传染病（如肝炎（例如HCV，HBV），遗传相关病毒感染和癌症在内的各种治疗领域中具有用途。
• [EN] MACROCYCLIC DEAZA-PURINONES FOR THE TREATMENT OF VIRAL INFECTIONS<br/>[FR] DÉAZA-PURINONES MACROCYCLIQUES POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014154859A1

  公开（公告）日：2014-10-02

  This invention relates to macrocyclic deaza-purinones derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

  这项发明涉及大环脱氮嘌呤酮衍生物，其制备方法，药物组合物以及它们在治疗病毒感染中的应用。
• Adsorption of immunopotentiators to insoluble metal salts
  申请人：Singh Manmohan

  公开号：US09315530B2

  公开（公告）日：2016-04-19

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以被吸附到不溶性金属盐，如铝盐，以修改它们的药代动力学、药效动力学、肌肉内滞留时间和/或免疫刺激效应。免疫增强剂被改性以引入一种基团，如膦酸盐基团，可以介导吸附。这些改性化合物即使以吸附形式投递，也可以保留或改善它们在体内的免疫活性。
• Formulation of immunopotentiators
  申请人：Singh Manmohan

  公开号：US20120177681A1

  公开（公告）日：2012-07-12

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以被吸附到不溶性金属盐中，例如铝盐，以修改它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被改性以引入一个基团，例如膦酸盐基团，可以介导吸附。即使以吸附形式传递，这些改性化合物也可以保留或改善它们在体内的免疫活性。
• ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS
  申请人：Singh Manmohan

  公开号：US20130274465A1

  公开（公告）日：2013-10-17

  Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

  免疫增强剂可以吸附到不溶性金属盐上，例如铝盐，以改变它们的药代动力学、药效学、肌肉内滞留时间和/或免疫刺激作用。免疫增强剂被修改以引入一个基团，例如磷酸酯基团，可以介导吸附。即使以吸附形式输送，这些修改的化合物仍然可以保持或改善它们的体内免疫活性。